Background-Human genomes harbor copy number variants (CNVs), which are regions of DNA gains or losses. Although pathogenic CNVs are associated with congenital heart disease (CHD), their effect on clinical outcomes is unknown. This study sought to determine whether pathogenic CNVs among infants with single ventricle physiology were associated with inferior neurocognitive and somatic growth outcomes. Methods and Results-Genomic DNAs from 223 subjects of 2 National Heart, Lung, and Blood Institute-sponsored randomized clinical trials in infants with single ventricle CHD and 270 controls from The Cancer Genome Atlas project were analyzed for rare CNVs >300 kb using array comparative genomic hybridization. Neurocognitive and growth outcomes at 14 months from the CHD trials were compared among subjects with and without pathogenic CNVs. Putatively pathogenic CNVs, comprising 25 duplications and 6 deletions, had a prevalence of 13.9%, significantly greater than the 4.4% rate of such CNVs among controls. CNVs associated with genomic disorders were found in 13 cases but not in controls. Several CNVs likely to be causative of single ventricle CHD were observed, including aberrations altering the dosage of GATA4, MYH11, and GJA5. Subjects with pathogenic CNVs had worse linear growth, and those with CNVs associated with known genomic disorders had the poorest neurocognitive and growth outcomes. A minority of children with pathogenic CNVs were noted to be dysmorphic on clinical genetics examination.
C ongenital heart disease (CHD) care has advanced remarkably during the past 40 years. 1 This has shifted focus to decreasing morbidity and improving neurological and developmental outcomes, which are affected by genetic factors. For example, aneuploidies and genomic lesions, such as 22q11.2 deletions, are associated with poorer neurocognitive outcomes. For most cases of CHD, however, the underlying genetic basis remains unknown. Identification of causative genetic factors could help to explain a larger percentage of the variance in CHD outcomes and might be useful for patient management and clinical trial design.
Copy number variants (CNVs), which are regions of DNA gains or losses >1000 base pairs, 2 are detectable as a result of recent advances in molecular cytogenetics, particularly using microarray-based methods. Using high-resolution, whole-genome scanning methods, it has become evident that a significant proportion of the normal healthy human genome harbors benign CNVs. 3, 4 A smaller subset of CNVs, more often large and de novo, are considered pathogenic and are increasingly associated with diseases such as schizophrenia and intellectual and developmental disabilities (IDD). [5] [6] [7] [8] Pathogenic CNV prevalence in CHD has been estimated to be 5% to 15%. [9] [10] [11] [12] [13] [14] [15] [16] [17] Two small-to modest-sized studies of patients with hypoplastic left heart syndrome (HLHS), a single ventricle (SV) form of CHD, have suggested that CNV frequency is not increased for that heart lesion. 12, 17 CNVs seem to be present at higher rates among patients with CHD plus extracardiac or developmental abnormalities, [9] [10] [11] [12] although roles for de novo CNVs causing isolated CHD have also been observed. 13, 14 No previous study of CNVs has included careful follow-up of outcomes, particularly growth and neurocognitive development, in children with CHD.
Methods

Study Cohort
Study participants from the Pediatric Heart Network's Infants with Single Ventricle (ISV) and Single Ventricle Reconstruction (SVR) trials were combined into a single cohort based on the similarity of their demographics, assessment tools, and CHD lesions as previously described. 18, 19 Additional subject demographics are provided in the online-only Data Supplement. Genomic DNAs (gDNAs) and outcome data were provided anonymously through the New England Research Institute. The protocol was deemed exempt by the Mount Sinai Institutional Review Board.
Genomic DNA Samples
The quality and quantity of gDNA for each sample were examined via NanoDrop (Thermo Fisher Scientific, Waltham, MA). For partially degraded or insufficient (<500 ng) samples as determined by agarose gel electrophoresis, whole-genome amplification was performed using the GenomePlex Complete Whole-Genome Amplification Kit (Sigma-Aldrich, St. Louis, MO) as described by the manufacturer.
Array Comparative Genomic Hybridization
Array comparative genomic hybridization (aCGH) was performed on microarrays according to the manufacturer's instructions (Agilent Human CGH 1×244A; Agilent Technologies, Santa Clara, CA). The data were analyzed with DNA Analytics 5.0.14 software (Agilent Technologies) via the aberration detection method-1 algorithm with a sensitivity threshold of 6.0 and a data filter rejecting aberrations with <5 probes with a log 2 ratio of ±0.25.
CNV Characterization
CNVs were considered pathogenic if they were >300 kb in size, contained genes, 20 and were either novel or well established as abnormal 21, 22 (Figure 1 ). Novelty was determined by comparing CNVs with the Database of Genomic Variants (DGV; http://projects.tcag.ca/variation/). CNVs were deemed polymorphisms if there was >50% overlap with CNVs already cataloged in the DGV, unless they were well established in the literature as associated with a genomic disorder. Putatively pathogenic CNVs were also checked against CNV data from 2500 controls released by the Eichler group 23 and against a set of pathogenic CNVs identified from a proprietary database of >40 000 individuals, most of whom had IDD, at Signature Genomic Laboratories (SGL). CNVs that were observed infrequently or deemed pathogenic in the SGL system 24 were designated as pathogenic for our study.
CNV Confirmation
Putatively pathogenic CNVs were confirmed via quantitative polymerase chain reaction using the Universal Probe Library (Roche, Indianapolis, IN) system (details in the online-only Data Supplement).
Pathogenic CNV Inheritance
For 12 SVRII subjects harboring pathogenic CNVs, 1 or both parental gDNAs were available (n=19) and analyzed for those CNVs with quantitative polymerase chain reaction.
Normal Controls
Two hundred seventy controls were obtained from The Cancer Genome Atlas Project (TCGA). We used aCGH data from peripheral blood gDNAs of subjects with solid tumors, either glioblastoma multiforme or ovarian cancer. Of note, an aged-matched control group would have been inferior because some neonates are destined to have IDD, often related to pathogenic CNVs. Adults enrolling in cancer clinical trials provide a better healthy comparison for the outcomes of interest. We eliminated the possibility of missing CNVs associated with early lethality by interrogating DGV and the SGL database.
The TCGA blood gDNAs were analyzed at the Dana Farber Cancer Institute using a custom 415K array (Agilent Technologies), which included 230 000 of the 244 000 probes used for the CHD cases. Reference DNA was from Promega, as for the CHD cases. The raw aCGH data were reanalyzed identically to the cases. All pathogenic CNVs (>300 kb) identified in CHD cases and TCGA controls would have been called using the other array.
Neurocognitive and Somatic Growth Outcomes
Subjects were dichotomized into subgroups of those with pathogenic CNVs (referred to as genotype+) and those without pathogenic CNVs (referred to as genotype−) and compared according to entry characteristics (sex, race/ethnicity, birth weight, and cardiac diagnoses). Subgroups were also assessed with respect to neurocognitive function using the mental developmental index (MDI) and psychomotor developmental index (PDI) measured with the Bayley scales of infant development II at 14 months of age. Growth outcomes at 14 months of age were compared (weight-, height-, and head circumference-forage Z scores and weight-for-height Z scores). For SVRII subjects, clinical or research genetic evaluations at 14 months of age were used for subgroup analysis. 25 
Statistical Analysis
Comparisons of demographic characteristics between the subgroup of 223 subjects included in this study and the larger cohort from which they were derived and of those with and without CNV were based on Fisher exact tests for categorical measures and t tests for continuous measures. Normality was tested using the Shapiro-Wilk test and confirmed by the observed distribution. Secondary analyses with other subgroups were not adjusted for the multiplicity of comparisons. Z scores for height, weight, and head circumference for age were calculated from the measured values using the National Health and Nutrition Examination Survey (http:// www.cdc.gov/nccdphp/dnpa/growthcharts/resources/sas.htm). t Tests were used to compare neurocognitive and somatic growth measurements among those with CNV gains and losses and those without CNVs. All tests were performed at the 0.05 level.
Results
We studied 82 ISV-only subjects, 113 SVRII-only subjects, and 28 subjects enrolled in both trials. Among these 223 subjects, 147 were men (66%). Racial composition was 85% white, 11% black, and 4% other or unknown. All enrolled subjects had SV forms of CHD, 76% being HLHS. No statistically significant difference in demographic characteristics was noted between our subjects derived from the ISV and SVRII cohorts and the larger cohorts from which they were obtained.
Pathogenic CNVs were detected in 31 subjects (13.9%; Table 1 ). The median sizes of the 25 duplications and 6 deletions were 674 kb and 1.5 Mb, respectively. Twenty-nine CNVs were successfully confirmed by quantitative polymerase chain reaction. Two other CNVs, for which there was insufficient DNA, were confirmed after whole-genome amplification using aCGH with a 105K Agilent array. The demographic characteristics, including birth weight, gestational age, sex, race, and ethnicity, were not significantly different among these 31 subjects with pathogenic CNVs compared with the 192 subjects without such CNVs ( Table I in the online-only Data Supplement). Cardiac anatomy also did not differ with genotype (HLHS: genotype+ 84% versus genotype− 75%, not significant).
Among the TCGA controls, 164 had glioblastoma multiforme and 106 had ovarian cancer, resulting in a female predominance (64.5%). The racial composition was 87% white, 6.6% black, and 6.4% other or unknown. Pathogenic CNVs were observed in 12 individuals (4.4%; Table II in the onlineonly Data Supplement). The median sizes of the 9 duplications and 3 deletions were 675 and 326.6 kb, respectively.
A statistically significant increase in pathogenic CNVs was observed in the CHD population relative to the TCGA cohort (13.9% versus 4.4%; P=0.0003 from the Fisher exact test). The ratios of pathogenic gain and loss CNVs were similar between the CHD and TCGA cohorts (CHD, 25:6; TCGA, 9:3; P=0.69).
Analysis of parental gDNAs of 12 SVRII subjects harboring pathogenic CNVs revealed inherited lesions in 3 of 7 for whom both parents were assessed and in 3 of 5 for whom 1 parent was analyzed (Table 1) .
To examine possible effects of pathogenic CNVs on health outcomes, neurocognitive and somatic growth measurements were compared between the genotype+ and genotype− cohorts ( Table 2 ; details by subject with pathogenic CNV are given in Table III in the online-only Data Supplement). Genotype+ subjects were significantly shorter by an average of 0.65 z score (P=0.031). No other significant difference was observed. For the genotype+ subgroups with gain or loss CNVs (Table 2) , the PDI scores were significantly lower among children who harbored loss CNVs than those in the genotype− cohort (P=0.032). The MDI scores also trended lower among those with deletions but did not achieve statistical significance in this small cohort (P=0.29).
Among the 31 pathogenic CNVs found among the CHD subjects, 13 (42%) have previously been associated with genomic disorders (Table 1 ). The demographics of this group did not differ from the genotype− cohort ( Table I in the onlineonly Data Supplement), and 77% had HLHS. Compared with the genotype− cohort, the 11 children with known CNVs for whom 14-month outcomes were available had the worst outcomes with globally reduced neurocognitive development (MDI and PDI) and the slowest growth.
To determine the sensitivity of clinical examination in detecting children with CHD who harbored pathogenic CNVs, we reviewed the data of 116 subjects from the SVR study genotyped in our study who had been evaluated by a clinical geneticist. Four children (3.4%) were diagnosed with known genetic syndromes, and an additional 29 (25%) were observed to have ≥1 dysmorphic features and extracardiac malformations. Of interest, none of the 14 subjects with a putatively pathogenic CNV who had a clinical genetic evaluation was diagnosed with a syndrome, and only 3 (21%) had dysmorphic features or extracardiac malformations. Seven of those 14 subjects harbored CNVs previously associated with genomic disorders; 2 of those had dysmorphic features or extracardiac malformations.
The outcomes for the 18 subjects with a genetic syndrome or a putatively pathogenic CNV were worse than those for the 69 children without genetic abnormalities, dysmorphic features, or extracardiac malformations with lower PDI scores, weights, and lengths ( Table 3 ). The outcomes for the 29 individuals with dysmorphic features and extracardiac malformations but without a genetic diagnosis or pathogenic CNV did not differ from the 69 subjects without genetic abnormalities, dysmorphic features, or extracardiac malformations. Inclusion of subjects with only dysmorphic features or extracardiac malformations to those without genetic abnormality provides the same conclusions about the inferior outcomes for children with a genetic syndrome or pathogenic CNV.
Discussion
Here, we provide a case-control study of the role of pathogenic CNVs in the cause of SV heart defects, particularly HLHS, and the first study to relate pathogenic CNVs to formal outcome assessments for children with CHD but without a known syndrome. Based on our results, SV forms of CHD are associated with a 10% excess of pathogenic CNVs, which may underestimate their importance. For the ISV and SVR trials, gDNAs were procured after the stage II operations. Because the 12-month mortality in the SVR trial was ≈30%, we were unable to assess CNV frequency in most subjects who died during these trials. A birth cohort study is needed to determine pathogenic CNV prevalence among those not surviving. We also suspect that some CNVs <300 kb, ignored in the present study, may be pathogenic. They were not included because public databases are far less populated for smaller CNVs, making separation of benign polymorphic CNVs from pathogenic ones less accurate.
Although we were only able to analyze a limited number of parents, it seems that ≈50% of the pathogenic CNVs are inherited. Three of the 6 inherited pathogenic CNVs altered a region on chromosome 16p13.1, an established genomic disorder with variable expressivity and incomplete penetrance. 26 Because parents were not examined, we cannot exclude that those harboring these pathogenic CNVs had subtle phenotypes.
The 4.4% rate of pathogenic CNVs among controls has plausible explanations. As noted above, CNVs associated with genomic disorders are incompletely penetrant. An excess of second-site CNVs has been found among individuals with CNVs associated with variable phenotypes. 27 Although no large second-site CNV was observed in our study, other mutations were not excluded. Finally, CNVs labeled as pathogenic could also be false-positives.
With our secondary analyses, we examined the outcomes among several subgroups, such as subjects with pathogenic gain or loss CNVs and known genomic lesions. A limitation of this study is that these subgroups were small, underpowering those analyses. Specifically, secondary comparisons were not adjusted for multiple hypothesis testing.
The most commonly identified pathogenic CNVs in our CHD cohort were 3 overlapping duplications and a deletion at chromosome 16p13.1 (Figures 2 and 3) . CNVs were previously associated with IDD, neuropsychiatric disorders, aortic dissection, and other forms of CHD. [28] [29] [30] [31] Compared with 8329 controls from a recent study, 5 16p13.1 duplications were significantly enriched in our CHD cohort (P=0.004). Among the 8 genes in the region, MYH11 and ABCC6 are of interest because MYH11 mutations are associated with aortic aneurysm and bicuspid aortic valve, and ABCC6 mutations cause pseudoxanthoma elasticum. 29, 32, 33 In addition to possible etiologic relevance for CHD, parents carrying loss CNVs may be at risk for aortic aneurysm.
We identified gain and loss CNVs altering GATA4 dosage. GATA4 point mutations cause CHD, 34 and deletions also altering neighboring genes underlie CHD with IDD. 35, 36 Our subject with the GATA4 deletion had a PDI score of 53, >1 SD below the mean of our CHD cohort. Gain CNVs altering GATA4 gains have also been associated with CHD, including HLHS, and may be associated with IDD. 37, 38 We observed a subtelomeric loss CNV at 12p13.33 (Figure 2 ), which has been associated with IDD with or without CHD. 39 The subject harboring this CNV had a PDI score of 50. We identified 3 nearly identical duplications at 16p11.2, which have been implicated in IDD and neuropsychiatric disease. [40] [41] [42] Although the PDI score in 1 subject harboring this CNV was 50, outcomes were not inferior in the other 2. Interestingly, deletions at 16p11.2 have also been associated with aortic valvular defects. 43 We detected 2 distal 1q21.1 duplication CNVs, which have previously been associated with CHD, particularly nonsyndromic tetralogy of Fallot, 13, 44 and poor neurocognitive and growth outcomes. 45 For the 1 child with this CNV with outcome results, there was marked global neurocognitive delay (MDI and PDI scores of 77 and 54, respectively) and poor growth (weightand height-for-age Z scores of −3.1 and −7.4, respectively).
Finally, 1 subject with double-inlet left ventricle harbored a de novo duplication altering 22q11.2, which has been linked to cardiac and extracardiac abnormalities 46, 47 and partially overlapped with the proximal region of the 22q11 distal deletion syndrome. 48, 49 This individual had a PDI score of 56.
The most interesting novel CNV was the 18p11.31-p11.2 duplication, which overlapped with a duplication in a patient with HLHS from the SGL database. Among the 40 000 individuals in that database, only 53 are known to have HLHS. PTPRM, the sole gene residing within the overlapping region for these 2 CNVs, seems to be relevant for cardiac development based on its expression pattern. At mouse embryonic day (E) 9.5, Ptprm is expressed in the endocardium, dorsal aortic and branchial arch endothelia, and portions of the brain 50 ; at E14.5, it is expressed most highly in the ascending aorta and at lower levels in the developing brain and lung. 51 Thus, PTPRM gains seem to be a new genomic lesion underlying HLHS.
With regard to the types of pathogenic CNVs detected, disproportionately more gains were observed than losses. In the general population, deletion CNVs exceed duplications by a 2:1 ratio. 2 Among individuals with neurocognitive disorders, de novo losses outnumber duplications by 3:1. 52 Similarly, children with CHD plus extracardiac abnormalities have an excess of deletions compared with duplications. Of interest, an excess of gain CNVs compared with losses was observed in children with isolated tetralogy of Fallot. 13 In our study, the most striking adverse effects on neurocognitive development and growth were observed among children with CNVs previously associated with genomic disorders, which included gains and losses, with a predominance of the former.
The subgroup of genotyped SVR subjects phenotyped by clinical geneticists provided interesting insights. Children harboring putatively pathogenic CNVs were not clinically obvious because none was diagnosed with a syndrome, and dysmorphic features or extracardiac malformations were not enriched. Most strikingly, >70% of the children with CNVs previously associated with genomic disorders had no dysmorphic feature or extracardiac anomaly. Of note, these CNVs would have been declared as abnormalities if clinical testing had been performed.
The findings from this study support the routine use of CNV testing in newborns with SV forms of CHD to enable better prognostication and early intervention. Similarly, the poorer linear growth associated with all pathogenic CNVs, the worse neurocognitive outcomes with deletions, and particularly the globally poor outcomes with CNVs associated with known genomic disorders could affect clinical trial outcomes depending on the designated end points. Thus, future CHD clinical trials might benefit from an incorporation of CNV status when determining entry criteria or randomization strategies. 
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